Approaches to pharmacy benefit management and the impact of consumer cost sharing

Clinical Therapeutics

Volumn 25, Issue 1, 2003, Pages 250-272

  Olson, Bridget M ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

Health insurance; Managed care; Pharmacy benefit management; Pharmacy benefits; Prescription drug insurance

Indexed keywords

COST; HEALTH CARE DELIVERY; HEALTH CARE PLANNING; HEALTH CARE UTILIZATION; MANAGED CARE; MEDLINE; PHARMACY BENEFIT MANAGER; PRESCRIPTION; REVIEW;

EID: 0037279349     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(03)90035-X     Document Type: Review

References (76)

1. Heffler S, Smith S, Won G, et al. Health spending projections for 2001-2011: The latest outlook. Faster health spending growth and a slowing economy drive the health spending projection for 2001 up sharply. Health Aff. 2002;21:207-218.
2. Coons SJ. "Managing" care: We can't have it all. Clin Ther. 2002;24:458-459.
3. Harris Interactive Health Care News. As corporate concerns about health care costs continue to rise, many employers plan to shift more costs to their employees. Available at: hup://www.harrisinteractive.com/news/allnewsbydate.asp?NewsID=372. Accessed September 9, 2002.
4. International Society of Certified Employee Benefit Specialists. Employer-sponsored prescription drug benefits - a closer look. Survey Results, December 2000. Available at: http://www.iscebs.org/pdf/census00.pdf. Accessed September 9, 2002.
5. Reutzel TJ. The nature and consequences of policies intended to contain costs in outpatient drug insurance programs. Clin Ther. 1993;15:752-764.
6. Litton LM, Sisk FA, Akins ME. Managing drug costs: The perception of managed care pharmacy directors. Am J Manag Care. 2000;6:805-814.
7. AdvancePCS Advisor. 2001 Drug Trends Report. Irving, Tex: Advance PCS; 2001.
8. Lehman GO. Business coalitions are responding to rising drug costs. Manag Care Interface. 2000;13:71-73.
9. Grabowski H, Mullins CD. Pharmacy benefit management, cost-effectiveness analysis and drug formulary decisions. Soc Sci Med. 1997;45:535-544.
10. Taniguchi R. Pharmacy benefit management companies. Am J Health Syst Pharm. 1995;52:1915-1917.
11. Sica JM. Managing prescription drug costs. Employee Benefits J. 2001;26:35-40.
12. Segedin DA. Three-tier co-payment plans: Design considerations and effectiveness. Drug Benefit Trends. 1999;11:43-52.
13. Scott MB. Effective management of prescription drug benefit is crucial to health care cost containment. Employee Benefit Plan Rev. 2001;55:21-22.
14. Pharmacy Benefit Management Institute, Inc. Wyeth-Ayerst Prescription Drug Benefit Cost and Plan Design Survey Report. Albuquerque, NM: Wellman Publishing, Inc; 2000.
15. Pharmacy Benefit Management Institute, Inc. Takeda and Lilly Prescription Drug Benefit Cost and Plan Design Survey Report. Albuquerque, NM: Wellman Publishing, Inc; 2001.
16. Motheral B, Fairman K, Teitelbaum F, et al. Pharmacy benefit management factors influencing utilization and costs in a pharmacy benefit program. Drug Benefit Trends. 1996;8:10-12,15-18,34.
17. Dalzell MD. Pharmacy copayments: A double-edged sword. Manag Care. 1999;8:26-31.
18. Rubin RJ, Dietrich KA, Hawk AD. Clinical and economic impact of implementing a comprehensive diabetes management program in managed care. J Clin Endocrinol Metab. 1998;83:2635-2642.
19. Soumerai SB, Avorn J, Ross-Degnan D, Gortmaker S. Payment restrictions for prescription drugs under Medicaid. Effects on therapy, cost, and equity. N Engl J Med. 1987;317:550-556.
20. Soumerai SB, Ross-Degnan D, Avorn J, et al. Effects of Medicaid drug-payment limits on admission to hospitals and nursing homes. N Engl J Med. 1991;325:1072-1077.
21. Smalley WE, Griffin MR, Fought RL, et al. Effect of a prior-authorization requirement on the use of nonsteroidal antiinflammatory drugs by Medicaid patients. N Engl J Med. 1995;332:1612-1617.
22. MacKinnon NJ, Kumar R. Prior authorization programs: A critical review of the literature. J Manag Care Pharm. 2001;7:297-302.
23. Herrier RN, Spencer JR, Davis CD. Case study using descriptive analysis to estimate hidden costs in processing third party prescriptions. J Am Pharm Assoc. 2000;40:658-665.
24. Soumerai SB, Lipton HL. Computer-based drug utilization review - risk, benefit, or boondoggle? N Engl J Med. 1995;332:1641-1645.
25. Fulda TR, Valuck R, Zanden J, et al. Disagreement among drug compendia on inclusion and ratings of drug-drug interactions. Curr Ther Res Clin Exp. 2000;61:540-548.
26. Lyles A, Sleath B, Fulda TR, Collins TM. Ambulatory drug utilization review: Opportunities for improved prescription drug use. Am J Manag Care. 2001;7:75-81.
27. Sleath B, Konrad TR, Fulda T, Collins TM. Medicaid drug utilization review and managed care: The perspectives and experiences of state program directors. J Manag Care Pharm. 2000;6:131-136.
28. Lyles A, Zuckerman IH, DeSipio SM, Fulda T. When warnings are not enough: Primary prevention through drug use review. Health Aff. 1998;17:175-183.
29. Kidder D, Bae J. Evaluation results from prospective drug utilization review: Medicaid demonstrations. Health Care Financ Rev. 1999;20:107-118.
30. Smith DH, Christensen DB, Stergachis A, Holmes G. A randomized controlled trial of a drug use review intervention for sedative hypnotic medications. Med Care. 1998;36:1013-1021.
31. Collins TM, Mott DA, Bigelow WE, Zimmerman DR. A controlled letter intervention to change prescribing behavior: Results of a dual-targeted approach. Health Servic Res. 1997;32:471-489.
32. Rascati KL, Okano GJ, Butch C. Evaluation of physician intervention letters. Med Care. 1996;34:760-766.
33. Hofer TP, Hayward RA, Greenfield S, et al. The unreliability of individual physician "report cards" for assessing the costs and quality of care of a chronic disease. JAMA. 1999;281:2098-2105.
34. Seltzer JK, Kurt TL, Knodel LC, et al, and the Texas Medicaid Vendor Drug Program Drug Utilization Review Board. Drug utilization review of sedative/hypnotic agents in Texas Medicaid patients. J Am Pharm Assoc. 2000;40:495-499.
35. Moore WJ, Gutermuth K, Pracht EE. Systemwide effects of Medicaid retrospective drug utilization review programs. J Health Polit Policy Law. 2000;25:653-688.
36. Motheral B, Delate T, Shaw J, Henderson R. The effect of a closed formulary in the face of real-life enrollment and disenrollment patterns. J Manag Care Pharm. 2000;6:293-297.
37. Rucker TD, Schiff G. Drug formularies: Myths-in-information. Med Care. 1990;28:928-942.
38. Motheral BR, Henderson R. The effect of a closed formulary on prescription drug use and costs. Inquiry. 1999;36:481-491.
39. Horn SD, Sharkey PP, Tracy DM, et al. Intended and unintended consequences of HMO cost-containment strategies: Results from the Managed Care Outcomes Project. Am J Manag Care. 1996;2:253-264.
40. Kravitz RL, Romano PS. Managed care cost containment and the law of unintended consequences. Am J Manag Care. 1996;2:323-324.
41. Gibaldi M. Drug formularies & health care costs: In God We Trust; The rest must show data. University of Washington Pharmaceutical Outcomes Research & Policy Program [newsletter]; 1996. Vol. 2, No. 2.
42. Bloom BS, Jacobs J. Cost effects of restricting cost-effective therapy. Med Care. 1985;23:872-880.
43. Soumerai SB, Ross-Degnan D, Fortess EE, Abelson J. A critical analysis of studies of state drug reimbursement policies: Research in need of discipline. Milbank Q. 1993;71:217-252.
44. Schneeweiss S, Maclure M, Walker AM, et al. On the evaluation of drug benefits policy changes with longitudinal claims data: The policy maker's versus the clinician's perspective. Health Policy. 2001;55:97-109.
45. Johnson JA, Coons SJ, Hays RD, et al. A comparison of satisfaction with mail versus traditional pharmacy services. J Manag Care Pharm. 1997;3:327-337.
46. Health Industries Research Companies (HIRC). Employers shifting more responsibility to employees. Available at: http://www.hirco.com/index.cfm/Fuseaction/ViewNews/ID/10.htm. Accessed September 27, 2001. [Business Wire summary available at http://special.northernlight.com/managedcare/shifting_responsibility.htm. Accessed September 26, 2002.]
47. Leibowitz A, Manning WG, Newhouse JP. The demand for prescription drugs as a function of cost-sharing. Soc Sci Med. 1985;21:1063-1069.
48. Lohr KN, Brook RH, Kamberg CJ, et al. Use of medical care in the RAND Health Insurance Experiment. Diagnosis- and service-specific analyses in a randomized controlled trial. Med Care. 1986;24(Suppl 9):S1-S87.
49. Merck-Medco Managed Care LLC. Merck-Medco Drug Trend Report, 2001. Franklin Lakes, NJ: Merck-Medco; 2001.
50. Reuters Health Information. Blue Cross of Michigan offers coupons for generic drugs. Available at: http://pharmacists.medscape.com. December 18, 2001. Accessed January 2, 2002.
51. Burstall ML. Copayments for medicines. How much should patients pay? Pharmacoeconomics. 1994;6:187-192.
52. William M. Mercer, Incorporated. Health benefit cost up 11.2% in 2001 - Highest jump in 10 years. National Survey of Employer Sponsored Health Plans 2001. W.M. Mercer News Release, December 10, 2001.
53. Carey G. Multi-tier copay: Opportunity or challenge? Pharm Exec. 2000;20:71-78.
54. Giaquinta D. Pharmacy management and three-tier copays: Cost management or cost shifting. Manag Care Interface. 2000;13:64-65.
55. Scott-Levin. Benefit design: How it's changing managed care. Managed Care Formulary Drug Audit, 2000. Research Triangle Park, NC: Quintiles Transnational Corporation; 2001.
56. Pharmacy Benefit Management Institute, Inc. Use of multiple-tier plan designs continues to increase. Available at: http://www.pbmi.com/V6N4_plandesigns.html. 2001. Accessed September 9, 2002.
57. Perlstein S. Four-tier approach injects consumerism into drug benefit. Available at: http://www.managedcaremag.com/archives/0108/0108.fourtier.html. Accessed December 5, 2002.
58. Fendrick AM, Smith DG, Chernew ME, Shah SN. A benefit-based copay for prescription drugs: Patient contribution based on total benefits, not drug acquisition cost. Am J Manag Care. 2001;7:861-867.
59. Saul A. Multitier co-pays emerge at two managed care groups. Drug Topics. August 21, 2001: 24.
60. The Henry J. Kaiser Family Foundation. Kaiser Daily Report (12-12-01): Insurers looking to increase consumer cost-sharing by adding tiers to prescription drug coverage. 2001.
61. Mays G, Hurley R, Grossman J. Consumers face higher costs as health plans seek to control drug spending. Center for Studying Health System Change, Issue Brief [newsletter]; 2001. No. 45.
62. Health Industries Research Companies (HIRC). Three-tier copays reach 35% of IPA HMOs. Available at: http://www.hirco.com/index.cfm/Fuseaction/ViewNews/ID/9.htm. Accessed September 27, 2001. [Business Wire summary available at http://www.samha.co.za/articles/01%20July%203-tier.htm. Accessed September 26, 2002.]
63. Appleby J. Prescriptions could cost workers $50: New plan prices generics low, others much higher. USA Today. June 19, 2001; 1B.
64. Soumerai SB, Ross-Degnan D. Experience of state drug benefit programs. Health Aff. 1990;9:36-54.
65. Motheral BR, Henderson R. The effect of a copay increase on pharmaceutical utilization, expenditures, and treatment continuation. Am J Manag Care. 1999;5:1383-1394.
66. Danzon PM, Pauly MV. Insurance and new technology: From hospital to drugstore. Health Aff. 2001;20:86-100.
67. Reissman D. Have we pushed member copayments too far? Drug Benefit Trends. 2001;24.
68. Penna P. Ethical, practical, and business considerations in pharmacy benefit design. Manag Care Interface. 2000;13:64-67.
69. Tamblyn R, Laprise R, Hanley JA, et al. Adverse events associated with prescription drug cost-sharing among poor and elderly persons. JAMA. 2001;285:421-429.
70. Blais L, Boucher JM, Couture J, et al. Impact of a cost-sharing drug insurance plan on drug utilization among older people. J Am Geriatr Soc. 2001;49:410-414.
71. Johnson RE, Goodman MJ, Hornbrook MC, Eldredge MB. The effect of increased prescription drug cost-sharing on medical care utilization and expenses of elderly health maintenance organization members. Med Care. 1997;35:1119-1131.
72. Johnson RE, Goodman MJ, Hornbrook MC, Eldredge MB. The impact of increasing patient prescription drug cost sharing on therapeutic classes of drugs received and on the health status of elderly HMO members. Health Serv Res. 1997;32:103-122.
73. Harris Interactive Health Care News. Out-of-pocket costs are a substantial barrier to prescription drug compliance. Available at: http://www.harrisinteractive.com/news/allnewsbydate.asp?NewsID=393. Accessed September 9, 2002.
74. Hillman A, Pauly M, Escarce J, et al. Financial incentives and drug spending in managed care. Health Aff. 1999;18:189-200.
75. Motheral B, Fairman K. Effect of a three-tier prescription copay on pharmaceutical and other medical utilization. Med Care. 2001;39:1293-1304.
76. Johnson K, Chen M, Kathuria S, Grinnell K. Use of regression analysis to predict benefit tiers and resulting cost savings. J Manag Care Pharm. 2001;7:364. Abstract.